CEL-SCI to Present at 3rd Annual Sachs Cancer Bio Partnering & Investment Forum
19 February 2015 - 12:00AM
Business Wire
CEL-SCI Corporation (NYSE MKT:CVM), a late-stage oncology
company, announced that Geert Kersten, Chief Executive Officer,
will be presenting at the 3rd Annual Sachs Cancer Bio Partnering
& Investment Forum on Monday, February 23, 2015 at 3:30 p.m.
The Forum is being held at the New York Academy of Sciences.
About the 3rd Annual Sachs Cancer Bio Partnering &
Investment Forum
The 3rd Annual Sachs Cancer Bio Partnering & Investment
Forum is designed to bring together thought leaders from cancer
research institutes, patient advocacy groups, pharma and biotech to
facilitate partnering and funding/investment. Sachs forums are
recognized as the leading international stage for those interested
in investing in the biotech and life science industry and are
highly transactional. They draw together an exciting cross-section
of early-stage/pre-IPO, late-stage and public companies with
leading investors, analysts, money managers and pharmas. The New
York forum provides the additional interaction with the
academic/scientific and patient advocacy communities.
About CEL-SCI Corporation
CEL-SCI’s work is focused on finding the best way to activate
the immune system to fight cancer and infectious diseases. Its lead
investigational immunotherapy Multikine (Leukocyte Interleukin,
Injection) is currently being studied in a pivotal Phase III
clinical trial against head and neck cancer. If the study endpoint,
which is a 10% improvement in overall survival of the subjects
treated with Multikine treatment regimen as compared to subjects
treated with current standard of care only is satisfied, the study
results will be used to support applications which will be
submitted to regulatory agencies in order to receive from these
agencies commercial marketing approvals for Multikine in major
markets around the world. Additional clinical indications for
Multikine which are being investigated include cervical dysplasia
in HIV/HPV co-infected women, and the treatment of peri-anal warts
in HIV/HPV co-infected men and women. A Phase I trial of the former
indication has been completed at the University of Maryland. The
latter indication is now in a Phase I trial in conjunction with the
U.S. Navy under a CRADA (Cooperative Research and Development
Agreement).
CEL-SCI is also developing its LEAPS technology for the
treatment of pandemic influenza and as a potential therapeutic
vaccine against rheumatoid arthritis. The Company has recently
received a Phase I SBIR Grant from the National Institutes of
Health to develop LEAPS as a potential treatment for RA with
researchers from Rush University Medical Center in Chicago,
Illinois. The Company has operations in Vienna, Virginia, and
in/near Baltimore, Maryland.
For more information, please visit www.cel-sci.com.
CEL-SCI CorporationGavin de Windt, 703-506-9460
Cel Sci (AMEX:CVM)
Historical Stock Chart
From Apr 2024 to May 2024
Cel Sci (AMEX:CVM)
Historical Stock Chart
From May 2023 to May 2024